Examkin

Foundational Science and Mechanisms of Disease

426 questions

All types426Multiple choice221Numeric17Matching95Ordering93
Question 161Question →

A series of hospitalized patients develop distinct drug-induced immunologic and inflammatory reactions. Match each specific clinical presentation to its precise underlying foundational pathophysiologic mechanism.

Click a left item, then click its matching right item

Items

A 45-year-old man develops fever, diffuse maculopapular rash, and progressive respiratory distress one week after initiating abacavir for HIV infection.
A 60-year-old woman develops new-onset myalgias, arthralgias, and pleuritic chest pain after six months of hydralazine therapy, with a homogeneously positive ANA.
A 35-year-old man receiving intravenous vancomycin for bacteremia rapidly develops marked erythema and pruritus of the face, neck, and upper torso during the infusion.
A 70-year-old man on a proton pump inhibitor develops progressive acute kidney injury, sterile pyuria with eosinophils, and a mild systemic rash.

Matches

Show answer & explanation

Answer

Abacavir hypersensitivity matches with HLA-binding alteration. Hydralazine-induced lupus matches with DNA methylation inhibition. Vancomycin flushing matches with direct mast cell activation. Acute interstitial nephritis matches with hapten-mediated delayed T-cell response.
Each specific clinical scenario reflects a unique, high-yield mechanism of drug-induced immunopathology. Abacavir strictly relies on structural modification of the HLA-B*57:01 groove. Hydralazine induces lupus via epigenetic disruption (DNA hypomethylation) causing loss of central T-cell tolerance. Vancomycin causes direct pharmacologic (non-IgE) mast cell degranulation. Proton pump inhibitors cause AIN by acting as haptens that incite a Type IV cell-mediated response in the kidney.

Step-by-Step Solution

1
Analyze the abacavir vignette.
Identified as abacavir hypersensitivity syndrome. This requires screening for HLA-B*57:01 because the drug directly alters the HLA-binding groove, activating CD8+ T cells.
Recognizing the exact molecular pathogenesis of severe abacavir toxicity is essential for preventing potentially fatal rechallenge.
2
Analyze the hydralazine vignette.
Identified as drug-induced lupus erythematosus (DILE). Hydralazine acts via inhibition of DNA methylation, leading to anti-histone antibody formation.
Differentiating the mechanism of DILE from idiopathic SLE highlights why specific autoantibodies (anti-histone vs. anti-dsDNA) are formed.
3
Analyze the vancomycin vignette.
Identified as vancomycin flushing syndrome. This is an anaphylactoid reaction driven by direct, IgE-independent mast cell degranulation.
Understanding it is not a true IgE-mediated allergy dictates management (slowing the infusion rate rather than permanent contraindication).
4
Analyze the proton pump inhibitor vignette.
Identified as acute interstitial nephritis (AIN). This is classically a Type IV hypersensitivity where the drug acts as a hapten in the renal interstitium.
AIN requires recognition of a delayed, cell-mediated attack on haptenized renal proteins to justify the use of systemic corticosteroids if drug cessation is insufficient.

Key Concept

Foundational mechanisms of drug-induced immunopathologies (Type IV hypersensitivity, altered MHC presentation, haptenization, and direct mast cell activation).
Question 162Question →

A 62-year-old man undergoes emergent abdominal aortic aneurysm repair complicated by massive intraoperative hemorrhage. He experiences a 45-minute period of profound hypotension. Despite aggressive fluid resuscitation and blood transfusions, his serum creatinine rises from 0.9 mg/dL to 3.4 mg/dL over the next 48 hours, and urinalysis reveals muddy brown granular casts, indicating acute tubular necrosis. The pathogenesis of this condition involves a predictable cascade of cellular injury resulting from severe ischemia. Arrange the following subcellular pathophysiologic events in the chronological order in which they occurred within this patient's affected proximal tubular epithelial cells, from the initial ischemic insult to ultimate cell death.

Drag items to arrange them in the correct order

Show answer & explanation

Answer

Decrease in oxidative phosphorylation -> Failure of Na+/K+-ATPase -> Cellular swelling -> Massive calcium influx -> Irreversible membrane rupture.
Ischemic injury follows a predictable subcellular cascade. Hypoxia primarily halts mitochondrial oxidative phosphorylation, causing rapid ATP depletion. This energy deficit immediately disables the Na+/K+-ATPase pump, resulting in an influx of sodium and water, which manifests as cellular swelling and ribosome detachment (reversible changes). As ischemia persists, cellular calcium pumps also fail, leading to a massive cytosolic calcium influx. This excess calcium activates endogenous phospholipases, proteases, and endonucleases, which dismantle the cytoskeleton, nuclear chromatin, and lipid bilayer. The destruction of these structural components ultimately leads to irreversible plasma membrane rupture and the spillage of intracellular contents, defining coagulative necrosis.

Step-by-Step Solution

1
Identify the primary insult
Profound hypotension caused severe renal hypoperfusion and ischemia.
Establishing the type of injury determines the specific cellular cascade, which in this case is hypoxic-ischemic injury.
2
Determine the immediate biochemical consequence of ischemia
Loss of oxygen halts mitochondrial oxidative phosphorylation, leading to rapid ATP depletion.
Oxygen is the terminal electron acceptor in the electron transport chain; without it, ATP production ceases rapidly.
3
Identify the downstream effects of ATP depletion
Failure of energy-dependent pumps (Na+/K+-ATPase) occurs, leading to intracellular sodium accumulation and subsequent cellular swelling.
The Na+/K+-ATPase normally maintains ion gradients; its failure causes osmotic shifts leading to early, reversible cellular changes.
4
Determine the transition to irreversible injury
Severe membrane damage allows massive calcium influx, which activates degradative enzymes, culminating in plasma membrane rupture.
High intracellular calcium activates phospholipases and proteases that destroy the cell membrane, marking the hallmark of irreversible coagulative necrosis.

Key Concept

The chronological sequence of hypoxic-ischemic cellular injury progresses from ATP depletion to pump failure, reversible cellular swelling, calcium influx, and finally irreversible membrane rupture.
Question 163Question →

A 34-year-old woman comes to the clinic for follow-up evaluation of right leg pain and swelling. She has a history of an unprovoked left pulmonary embolism six months ago, for which she has been taking rivaroxaban. Her symptoms had completely resolved until three days ago, when she developed worsening right calf pain. Two weeks ago, she was diagnosed with active pulmonary tuberculosis and began treatment with a four-drug regimen containing rifampin, isoniazid, pyrazinamide, and ethambutol. Vital signs are within normal limits. Physical examination shows a swollen, erythematous, and tender right calf. A venous duplex ultrasound confirms a new acute deep vein thrombosis in the right popliteal vein. Which of the following pharmacokinetic principles best explains this patient's current presentation?

Show answer & explanation

Answer: Accelerated systemic elimination via hepatic enzyme induction

Answer

Accelerated systemic elimination via hepatic enzyme induction
The correct answer identifies that the patient's recurrent thrombosis is due to a well-known pharmacokinetic drug interaction. Rifampin is a potent inducer of the cytochrome P450 system (particularly CYP3A4) and the P-glycoprotein (P-gp) efflux transporter. Rivaroxaban relies heavily on CYP3A4 for metabolism and P-gp for excretion. The induction of these pathways markedly accelerates the clearance of rivaroxaban, dropping its plasma concentration below the therapeutic threshold and leaving the patient vulnerable to recurrent thromboembolic events.

Step-by-Step Solution

1
Analyze the patient's clinical presentation.
The patient developed a new deep vein thrombosis while supposedly fully anticoagulated on rivaroxaban.
Identifying a therapeutic failure (recurrent thrombosis) establishes that the anticoagulant effect is currently subtherapeutic.
2
Identify any recent changes to the patient's medication regimen.
The patient recently started a four-drug regimen for active tuberculosis, which includes rifampin.
New medications are the most common cause of sudden pharmacokinetic shifts leading to loss of efficacy.
3
Recall the pharmacokinetic properties of the involved medications.
Rivaroxaban is metabolized by CYP3A4 and is a substrate for the P-glycoprotein (P-gp) efflux transporter. Rifampin is a potent inducer of both CYP3A4 and P-gp.
Understanding the specific metabolic pathways allows for the identification of the exact drug-drug interaction mechanism.
4
Determine the clinical consequence of this interaction.
Induction of CYP3A4 and P-gp significantly accelerates the clearance of rivaroxaban, leading to subtherapeutic drug concentrations and subsequent clot formation.
This confirms that accelerated systemic elimination is the definitive cause of the patient's presentation.

Key Concept

Rifampin is a potent inducer of cytochrome P450 enzymes (specifically CYP3A4) and P-glycoprotein. Co-administration with direct oral anticoagulants (DOACs) like rivaroxaban accelerates their clearance, resulting in subtherapeutic levels and an increased risk of thromboembolism.
Question 164Question →

An 80-kg80 \text{-kg}, 60-year-old60 \text{-year-old} male patient is undergoing treatment in the intensive care unit for severe hospital-acquired pneumonia. The clinical team initiates continuous intravenous therapy with a novel narrow-therapeutic-index antimicrobial agent. The pharmacokinetic profile of this drug in the patient indicates a volume of distribution of 0.5 L/kg0.5 \text{ L/kg} and a systemic clearance of 0.04 L/hr/kg0.04 \text{ L/hr/kg}. The desired steady-state plasma concentration of the medication is 20 mg/L20 \text{ mg/L}.

To maintain this target steady-state concentration, what should be the continuous intravenous infusion rate in mg/hr?

Show answer & explanation

Answer: 64

Answer

64
To maintain a steady-state concentration of a drug, the rate of drug administration must equal the rate of drug elimination. The elimination rate is calculated as the product of the total systemic clearance and the target steady-state concentration. First, the total clearance is found by multiplying the weight-adjusted clearance by the patient's weight (0.04 L/hr/kg×80 kg=3.2 L/hr0.04 \text{ L/hr/kg} \times 80 \text{ kg} = 3.2 \text{ L/hr}). Then, the maintenance infusion rate is calculated by multiplying the total clearance by the target concentration (3.2 L/hr×20 mg/L=64 mg/hr3.2 \text{ L/hr} \times 20 \text{ mg/L} = 64 \text{ mg/hr}).

Step-by-Step Solution

1
Calculate the patient's total systemic clearance.
0.04 L/hr/kg×80 kg=3.2 L/hr0.04 \text{ L/hr/kg} \times 80 \text{ kg} = 3.2 \text{ L/hr}
Clearance is provided on a per-kilogram basis and must be scaled to the patient's actual body weight to determine the total drug elimination rate.
2
Calculate the continuous maintenance infusion rate.
3.2 L/hr×20 mg/L=64 mg/hr3.2 \text{ L/hr} \times 20 \text{ mg/L} = 64 \text{ mg/hr}
The maintenance dose rate is the product of clearance and the target steady-state concentration.

Key Concept

Maintenance dose rate is determined solely by the drug's clearance and the desired steady-state plasma concentration.
Question 165Question →

A 34-year-old industrial worker is brought to the emergency department by emergency medical services after his coworkers found him acutely confused and vomiting in a storage room. His coworkers report that for the past several hours, he had been cleaning old, degraded machinery in a poorly ventilated space using a previously restricted halogenated hydrocarbon solvent (carbon tetrachloride). He accidentally spilled a large quantity of the solvent on his clothing and inhaled the fumes. On arrival, his blood pressure is 110/70 mmHg, and his pulse is 105/min. Physical examination is notable for scleral icterus, right upper quadrant abdominal tenderness, and asterixis. Laboratory studies demonstrate an aspartate aminotransferase (AST) of 4,200 U/L and an alanine aminotransferase (ALT) of 4,500 U/L. Which of the following best describes the initial subcellular mechanism responsible for this patient's acute hepatic injury?

Show answer & explanation

Answer: Conversion of the molecule by the smooth endoplasmic reticulum into a highly reactive free radical

Answer

Conversion of the molecule by the smooth endoplasmic reticulum into a highly reactive free radical
Carbon tetrachloride (CCl4CCl_4) is a classic industrial hepatotoxin. Once it enters the body, it is delivered to the liver where the cytochrome P450 oxidase system—abundant in the smooth endoplasmic reticulum of hepatocytes—metabolizes it. This process generates the trichloromethyl free radical (CCl3∙CCl_3^\bullet). This highly reactive oxygen species immediately attacks the lipid-rich cellular and organelle membranes, a process known as lipid peroxidation. This causes the rough endoplasmic reticulum to swell and ribosomes to detach, leading to decreased protein synthesis (such as apolipoproteins, resulting in fatty change). Ultimately, the overwhelming membrane damage causes massive calcium influx, mitochondrial failure, and centrilobular necrosis, as evidenced by the extreme elevations in AST and ALT.

Step-by-Step Solution

1
Identify the patient's primary clinical presentation and exposure.
The patient has massive acute hepatocellular injury (AST and ALT > 4,000 U/L) following a large exposure to carbon tetrachloride (CCl4CCl_4).
Recognizing the specific toxicological agent is required to determine the precise pathophysiology of the cell injury.
2
Determine how the specific toxin interacts with the target organ's cellular machinery.
Carbon tetrachloride is rapidly absorbed and transported to the liver, where it is metabolized by the cytochrome P450 mixed-function oxidase system located in the smooth endoplasmic reticulum.
Toxins often require metabolic activation to cause tissue-specific damage.
3
Identify the downstream cellular consequences of this interaction.
The CYP450 system converts CCl4CCl_4 into the trichloromethyl free radical (CCl3∙CCl_3^\bullet), which initiates a catastrophic chain reaction of lipid peroxidation, leading to structural membrane breakdown and eventual centrilobular necrosis.
Understanding the transition from chemical interaction to morphological cell death defines the foundational mechanism of this injury.

Key Concept

The hallmark of carbon tetrachloride hepatotoxicity is its metabolism by the hepatic cytochrome P450 system into a highly reactive free radical, which causes devastating lipid peroxidation and subsequent cellular necrosis.
Question 166Question →

A 58-year-old man is hospitalized for pyelonephritis and bacteremia. Initial blood cultures grow *Enterobacter cloacae*. Antibiotic susceptibility testing indicates that the isolate is susceptible to ceftriaxone, and therapy with this agent is initiated. The patient initially improves, but on day 5 of hospitalization, he develops recurrent fever, tachycardia, and a rising leukocyte count. Repeat blood cultures grow *Enterobacter cloacae* that is now resistant to ceftriaxone, ceftazidime, and piperacillin-tazobactam, but remains susceptible to meropenem and amikacin. Which of the following best describes the molecular mechanism responsible for the pathogen's new resistance profile?

Show answer & explanation

Answer: Derepression of a chromosomal gene encoding an enzyme that hydrolyzes the beta-lactam ring

Answer

Derepression of a chromosomal gene encoding an enzyme that hydrolyzes the beta-lactam ring
The correct answer describes the derepression of the chromosomal AmpC beta-lactamase gene. Certain Gram-negative bacilli, often remembered by the mnemonic 'SPACE' or 'ESPM' (Enterobacter, Serratia, Pseudomonas, Morganella), harbor an inducible, chromosomal AmpC beta-lactamase gene. When these organisms are exposed to certain beta-lactam antibiotics like ceftriaxone, a mutant subpopulation that constitutively hyperproduces (derepresses) the AmpC enzyme is selected for. This results in clinical failure and widespread beta-lactam resistance, including resistance to third-generation cephalosporins and beta-lactamase inhibitors like piperacillin-tazobactam. Carbapenems, such as meropenem, are stable against AmpC hydrolysis and remain the treatment of choice for severe infections with these organisms.

Step-by-Step Solution

1
Analyze the clinical scenario and microbiology data
The patient has an Enterobacter cloacae infection that developed rapid resistance to 3rd-generation cephalosporins and beta-lactamase inhibitors while on ceftriaxone therapy, but retained susceptibility to carbapenems.
To identify the typical resistance pattern of the isolated organism.
2
Identify the primary resistance mechanism of the organism
Enterobacter cloacae has an inducible, chromosomally mediated AmpC beta-lactamase.
Matching the pathogen to its intrinsic genetic resistance capabilities.
3
Correlate the mechanism with the clinical presentation
Exposure to ceftriaxone selected for a derepressed mutant subpopulation that constitutively hyperproduces AmpC, explaining the new resistance to ceftriaxone and piperacillin-tazobactam.
To confirm that the resistance mechanism aligns with the drug susceptibilities provided.

Key Concept

Organisms with inducible chromosomal AmpC beta-lactamases (such as Enterobacter, Serratia, and Citrobacter) can rapidly develop resistance to third-generation cephalosporins during therapy due to derepression of the AmpC gene.
Question 167Question →

Review the following four clinical scenarios involving complex hemodynamic or coagulation abnormalities. Pair each patient's presentation with the primary molecular or physiologic mechanism responsible for their condition.

Click a left item, then click its matching right item

Items

A 3737-year-old man presenting with altered mental status, fever, petechiae, a platelet count of 18,000/μL18,000/\mu\text{L}, and normal prothrombin time and activated partial thromboplastin time.
A 6565-year-old woman with urosepsis who develops diffuse mucosal oozing, a platelet count of 25,000/μL25,000/\mu\text{L}, prolonged prothrombin time, prolonged activated partial thromboplastin time, and a plasma fibrinogen level of 80 mg/dL80 \text{ mg/dL}.
A 5858-year-old man who develops painful, violaceous, necrotic skin lesions on his thighs three days after initiating an oral medication for an acute pulmonary embolism.
A 2929-year-old woman with a history of recurrent mid-trimester miscarriages presenting with an unprovoked deep venous thrombosis and an isolated, prolonged activated partial thromboplastin time.

Matches

Show answer & explanation

Answer

The 37-year-old man with normal coagulation times matches with metalloproteinase inhibition (TTP). The 65-year-old woman with prolonged coagulation times and low fibrinogen matches with systemic activation of the coagulation cascade (DIC). The 58-year-old man with necrotic skin lesions matches with rapid depletion of a vitamin K-dependent endogenous anticoagulant (Warfarin-induced skin necrosis). The 29-year-old woman with an isolated prolonged aPTT matches with autoantibodies targeting phospholipid-binding proteins (Antiphospholipid syndrome).
Each clinical vignette provides classic diagnostic clues for a specific coagulation disorder, which must be paired with its underlying mechanism. TTP is mediated by ADAMTS13 deficiency. DIC is a consumptive coagulopathy triggered by systemic inflammation and tissue factor. Warfarin necrosis is driven by rapid protein C depletion. APLS involves autoantibodies causing in vivo thrombosis and paradoxical in vitro aPTT prolongation.

Step-by-Step Solution

1
Analyze the presentation of the 37-year-old man with altered mental status, fever, and severe thrombocytopenia.
Identify the diagnosis as Thrombotic Thrombocytopenic Purpura (TTP), which matches with autoantibody-mediated inhibition of the ADAMTS13 metalloproteinase.
The combination of severe thrombocytopenia, microangiopathic changes, and neurologic symptoms with normal PT and aPTT strongly distinguishes TTP from consumptive coagulopathies.
2
Evaluate the 65-year-old woman with urosepsis, diffuse oozing, thrombocytopenia, and hypofibrinogenemia.
Identify the diagnosis as Disseminated Intravascular Coagulation (DIC), which matches with systemic activation of the coagulation cascade by tissue factor.
Sepsis triggers massive tissue factor release, causing widespread microvascular thrombosis that consumes platelets and coagulation factors, leading to prolonged PT/aPTT and low fibrinogen.
3
Assess the 58-year-old man with necrotic skin lesions starting three days after initiating oral medication for a pulmonary embolism.
Identify the diagnosis as Warfarin-induced skin necrosis, which matches with the rapid depletion of a vitamin K-dependent endogenous anticoagulant.
Warfarin initially depletes Protein C (an endogenous anticoagulant with a short half-life) faster than procoagulant factors, creating a transient, severe hypercoagulable state.
4
Review the 29-year-old woman with recurrent miscarriages, venous thrombosis, and an isolated prolonged aPTT.
Identify the diagnosis as Antiphospholipid Syndrome (APLS), which matches with autoantibodies targeting phospholipid-binding proteins.
The lupus anticoagulant in APLS causes an in vitro aPTT prolongation by interfering with assay phospholipids, while paradoxically promoting severe in vivo hypercoagulability.

Key Concept

Differentiating consumptive, autoimmune, and pharmacologically-induced coagulopathies requires correlating the clinical context (e.g., sepsis, medication initiation) with specific laboratory patterns (e.g., normal versus prolonged PT/aPTT, fibrinogen levels).
Question 168Question →

Match each patient's clinical and histopathologic presentation with the primary molecular mechanism driving their underlying neoplastic process.

Click a left item, then click its matching right item

Items

A 65-year-old man presents with generalized lymphadenopathy. Biopsy shows an aggressive proliferation of small to medium-sized CD5-positive, CD23-negative B cells.
A 58-year-old woman with a history of painless, waxing and waning lymphadenopathy undergoes a biopsy showing nodular aggregates of neoplastic cells lacking tingible body macrophages.
A 48-year-old man presents with early satiety and massive splenomegaly. Labs show a leukocyte count of 85,000/mm385,000/\text{mm}^3 with a full spectrum of granulocytic differentiation and low leukocyte alkaline phosphatase.
A 25-year-old man presents with a rapidly expanding neck mass. Biopsy reveals uniform, medium-sized lymphoid cells with numerous mitotic figures and interspersed macrophages containing apoptotic debris.

Matches

Show answer & explanation

Answer

The correct pairings match Mantle cell lymphoma with cell cycle progression (Cyclin D1); Follicular lymphoma with inhibition of apoptosis (BCL-2); Chronic myeloid leukemia with activated tyrosine kinase signaling (BCR-ABL); and Burkitt lymphoma with transcription factor overexpression (c-Myc).
Each correct pairing accurately links the diagnostic clinical/pathologic features of a hematologic malignancy to the precise intracellular mechanism of its primary oncogenic driver (Cyclin D1 for Mantle Cell, BCL-2 for Follicular, BCR-ABL for CML, and c-Myc for Burkitt).

Step-by-Step Solution

1
Analyze each clinical vignette to identify the specific hematologic malignancy based on demographics, clinical behavior, and histopathologic or laboratory findings.
Identified Mantle cell lymphoma, Follicular lymphoma, Chronic myeloid leukemia, and Burkitt lymphoma.
Accurate pathologic diagnosis is required before the underlying molecular driver can be identified.
2
Recall the characteristic chromosomal translocation associated with each identified malignancy.
Mantle cell is t(11;14); Follicular is t(14;18); CML is t(9;22); Burkitt is t(8;14).
Chromosomal translocations are the initiating events in these specific neoplastic processes.
3
Connect the specific gene product of each translocation to its functional role in the cell to find the correct match.
t(11;14) = Cyclin D1 (G1-to-S phase); t(14;18) = BCL-2 (anti-apoptotic mitochondrial protein); t(9;22) = BCR-ABL (tyrosine kinase); t(8;14) = c-Myc (transcription factor).
Understanding the downstream molecular consequence is essential for correlating the disease with its targeted cellular mechanism.

Key Concept

Molecular pathogenesis of hematologic malignancies via specific chromosomal translocations.
Question 169Question →

A 68-year-old woman is admitted to the hospital with a 2-day history of acute-onset right leg pain and swelling. She has a history of type 2 diabetes mellitus, hypertension, and advanced chronic kidney disease. Her current medications include amlodipine, lisinopril, and insulin glargine. Vital signs are temperature 37.1°C (98.8°F), blood pressure 142/86 mm Hg, heart rate 88/min, and respiratory rate 16/min. Physical examination reveals pitting edema, erythema, and tenderness of the right lower extremity extending to the mid-thigh. Laboratory studies show:

Serum creatinine: 4.8 mg/dL (Estimated glomerular filtration rate: 11 mL/min/1.73 m²)
Platelet count: 180,000/mm³
Prothrombin time: 11 seconds
Partial thromboplastin time: 28 seconds

Compression ultrasonography of the right lower extremity confirms a deep vein thrombosis in the right femoral vein. The decision is made to initiate immediate systemic anticoagulation. Which of the following is the most appropriate initial pharmacotherapy for this patient?

Show answer & explanation

Answer: Intravenous unfractionated heparin

Answer

Intravenous unfractionated heparin
The correct answer is intravenous unfractionated heparin. This patient presents with an acute deep vein thrombosis and requires immediate systemic anticoagulation. A critical factor in selecting her therapy is her severe chronic kidney disease (eGFR 11 mL/min/1.73 m²). Unfractionated heparin is primarily metabolized by the reticuloendothelial system and macrophages. Its clearance is relatively unaffected by renal function, making it the safest and most appropriate initial choice for patients with an eGFR < 30 mL/min/1.73 m².

Step-by-Step Solution

1
Diagnose the acute condition requiring treatment.
The patient has an acute deep vein thrombosis (DVT) in the right femoral vein.
Compression ultrasonography confirmed the presence of the clot, establishing the need for immediate systemic anticoagulation.
2
Identify patient-specific modifiers that influence pharmacotherapy selection.
The patient has severe chronic kidney disease (CKD stage 5) with an eGFR of 11 mL/min/1.73 m².
Anticoagulants have varying degrees of renal clearance, and severe renal impairment significantly alters their safety profiles and contraindications.
3
Select the appropriate anticoagulant based on the patient's renal function.
Intravenous unfractionated heparin is selected as the initial therapy.
Unfractionated heparin is cleared by the reticuloendothelial system and does not pose an accumulation risk in severe renal failure, unlike low-molecular-weight heparins, fondaparinux, and most direct oral anticoagulants.

Key Concept

In patients with severe renal impairment (eGFR < 30 mL/min/1.73 m²), intravenous unfractionated heparin is the preferred initial anticoagulant for acute venous thromboembolism because it is primarily cleared by the reticuloendothelial system, avoiding the toxic drug accumulation seen with renally cleared agents.
Question 170Question →

Emergency medical services bring a 23-year-old woman to the resuscitation bay for rapid-onset throat swelling, voice changes, and difficulty swallowing that began two hours after a routine tooth extraction. She denies any new medications, food exposures, or known allergies. Her medical history is notable for three emergency department visits over the last four years for severe, colicky abdominal pain that was evaluated with computed tomography; each time, she was diagnosed with non-specific enteritis and symptoms resolved spontaneously within 48 hours. Her family history reveals that her father died suddenly of respiratory failure at age 35. On presentation, her blood pressure is 115/75 mm Hg, pulse is 102/min, and respirations are 24/min. Physical examination demonstrates massive non-pitting edema of the lips, tongue, and oropharynx. Urticaria and pruritus are completely absent. Stridor is audible. Intramuscular epinephrine, intravenous diphenhydramine, and intravenous methylprednisolone are administered immediately. Re-evaluation 30 minutes later reveals no improvement in her airway swelling. Which of the following is the primary molecular target of the most appropriate directed pharmacotherapy for this patient's current condition?

Show answer & explanation

Answer: Bradykinin B2 receptor

Answer

Bradykinin B2 receptor
The correct answer is the Bradykinin B2 receptor. This patient's presentation of trauma-induced angioedema without urticaria, history of recurrent abdominal pain, family history of sudden airway compromise, and lack of response to standard anaphylaxis therapy is classic for Hereditary Angioedema (HAE). HAE is caused by a deficiency in C1 esterase inhibitor, leading to unregulated activation of plasma kallikrein and massive overproduction of bradykinin. Bradykinin acts primarily on the B2 receptor to cause profound vasodilation and increased vascular permeability. Acute, life-threatening attacks require directed therapy to halt this cascade, commonly achieved with icatibant (a highly specific bradykinin B2 receptor antagonist), ecallantide (a kallikrein inhibitor), or C1-INH replacement. Therefore, the bradykinin B2 receptor is the precise molecular target among the choices provided.

Step-by-Step Solution

1
Analyze the clinical presentation to establish a diagnosis.
The combination of isolated angioedema triggered by minor trauma (tooth extraction), absence of urticaria/pruritus, recurrent unexplained abdominal pain (intestinal edema), positive family history of asphyxiation, and failure to respond to epinephrine and antihistamines strongly points to Hereditary Angioedema (HAE).
Differentiating bradykinin-mediated angioedema from histamine-mediated (allergic) anaphylaxis is critical, as their pathophysiologic mechanisms and acute treatments are entirely different.
2
Determine the pathophysiologic mechanism of the disease.
HAE is an autosomal dominant disorder caused by a deficiency or dysfunction of C1 esterase inhibitor (C1-INH).
Understanding the underlying defect allows for targeted pharmacologic intervention.
3
Trace the biochemical pathway resulting from the defect.
C1-INH normally inhibits both the classical complement pathway (C1r/C1s) and the contact-kinin system (Factor XIIa and plasma kallikrein). Uninhibited plasma kallikrein cleaves high-molecular-weight kininogen into bradykinin.
Excess bradykinin is the direct molecular culprit causing the severe vasodilation and vascular permeability seen in HAE.
4
Identify the target of the required acute pharmacotherapy.
Acute airway-threatening HAE attacks must be treated by interrupting the kinin cascade. This is achieved using a bradykinin B2 receptor antagonist (icatibant), a plasma kallikrein inhibitor (ecallantide), or purified C1-INH concentrate.
The question asks for the primary molecular target of the most appropriate directed pharmacotherapy, making the bradykinin B2 receptor the correct choice.

Key Concept

Hereditary angioedema is a bradykinin-mediated process unresponsive to epinephrine, antihistamines, and glucocorticoids; acute airway attacks require targeted therapies such as bradykinin B2 receptor antagonists (icatibant), kallikrein inhibitors (ecallantide), or C1 inhibitor concentrate.
Question 171Question →

A 54-year-old woman presents to the clinic with a chronic, productive cough that is particularly worse in the mornings. She has a 35-pack-year smoking history and no other significant medical history. Physical examination reveals scattered rhonchi that clear with coughing. Pulmonary function testing demonstrates an FEV1/FVC ratio of 65%. Given her significant smoking history and a recent mild episode of hemoptysis, a bronchoscopy is performed. Histological examination of a bronchial mucosal biopsy reveals the replacement of the normal ciliated pseudostratified columnar epithelium by stratified squamous epithelium. There is no evidence of cellular atypia or invasion. Which of the following is the most likely cellular mechanism underlying this histologic change?

Show answer & explanation

Answer: Reprogramming of local tissue stem cells toward a new differentiation pathway

Answer

Reprogramming of local tissue stem cells toward a new differentiation pathway
The patient's biopsy demonstrates squamous metaplasia, a classic adaptive response of the respiratory epithelium to chronic irritation from cigarette smoke. The fragile ciliated columnar epithelium is replaced by a more rugged stratified squamous epithelium. Mechanistically, this adaptation occurs because chronic irritation alters local cytokine and growth factor signaling, which in turn reprogram the local tissue stem cells (reserve cells) residing in the basal layer of the epithelium. These stem cells differentiate along a new squamous pathway instead of their usual columnar pathway. Mature columnar cells do not directly transform into squamous cells.

Step-by-Step Solution

1
Analyze the patient's clinical presentation and test results.
The patient has chronic obstructive pulmonary disease (COPD) from chronic smoking, leading to chronic irritation of the respiratory tract.
Establishing the nature of the environmental stressor helps predict the tissue's adaptive response.
2
Interpret the histological biopsy findings.
The biopsy shows normal ciliated pseudostratified columnar epithelium replaced by stratified squamous epithelium without atypia.
Identifying the change from one mature, normal cell type to another mature, normal cell type defines the process as metaplasia.
3
Identify the cellular mechanism driving this specific adaptation.
Metaplasia is driven by the genetic reprogramming of local tissue stem cells (reserve cells) rather than the direct transdifferentiation of existing mature cells.
Understanding the foundational mechanism of cellular adaptation is required to select the correct answer.

Key Concept

Metaplasia is a reversible cellular adaptation where one adult cell type is replaced by another adult cell type. It occurs through the reprogramming of local tissue stem cells, not through the direct transformation of mature cells.
Question 172Question →

An infectious disease specialist is preparing a grand rounds presentation on the diverse strategies that human pathogens use to evade the host immune system and establish productive infections. The presentation highlights several distinct mechanisms, including the subversion of cellular peptide transport, the secretion of immunomodulatory analogs, escaping intracellular degradation, and the constant alteration of surface antigens. Match the following pathogens to their corresponding primary molecular mechanism of immune evasion or intracellular survival.

Click a left item, then click its matching right item

Items

Epstein-Barr virus
Herpes simplex virus type 1
*Neisseria gonorrhoeae*
*Listeria monocytogenes*

Matches

Show answer & explanation

Answer

Epstein-Barr virus produces an IL-10 homolog; Herpes simplex virus type 1 inhibits the TAP complex; Neisseria gonorrhoeae undergoes pilin antigenic variation; and Listeria monocytogenes secretes a cytolysin to escape the phagolysosome.
Each pathogen has evolved unique molecular mechanisms to establish infection and evade host defenses. Epstein-Barr virus mimics host immunosuppressive cytokines, Herpes simplex virus blocks intracellular antigen presentation, Neisseria gonorrhoeae constantly alters its surface antigens via genetic recombination, and Listeria monocytogenes escapes destruction by physically breaking out of the phagolysosome.

Step-by-Step Solution

1
Analyze the immune evasion mechanism of Epstein-Barr virus (EBV).
EBV synthesizes a viral IL-10 homolog (BCRF1).
This cytokine analog suppresses Th1 cell activation and macrophage function, promoting viral persistence.
2
Analyze the intracellular survival strategy of Herpes simplex virus type 1 (HSV-1).
HSV-1 produces the ICP47 protein which binds to the Transporter Associated with Antigen Processing (TAP).
Inhibiting TAP prevents the loading of viral peptides onto MHC class I molecules, evading CD8+ cytotoxic T-cell recognition.
3
Identify the primary mechanism of evasion for Neisseria gonorrhoeae.
N. gonorrhoeae evades humoral immunity via extensive antigenic variation of its pili.
This is driven by homologous recombination between silent pilS cassettes and the active pilE expression locus.
4
Determine the pathogenesis of Listeria monocytogenes upon phagocytosis.
L. monocytogenes secretes listeriolysin O, a sulfhydryl-activated cytolysin.
This pore-forming toxin lyses the phagolysosome membrane, allowing the bacteria to escape into the host cell cytosol.

Key Concept

Specific molecular mechanisms of immune evasion and intracellular pathogenesis used by viral and bacterial pathogens.
Estimated Time:1m 30s
Question 173Question →

Match the following clinically significant drug combinations with the primary pharmacokinetic or pharmacodynamic mechanism underlying their interaction.

Click a left item, then click its matching right item

Items

Simvastatin and Clarithromycin
Lithium and Hydrochlorothiazide
Clopidogrel and Omeprazole
Digoxin and Verapamil

Matches

Show answer & explanation

Answer

Simvastatin and Clarithromycin matches CYP3A4 inhibition; Lithium and Hydrochlorothiazide matches enhanced proximal tubular reabsorption; Clopidogrel and Omeprazole matches CYP2C19 inhibition; Digoxin and Verapamil matches P-glycoprotein inhibition.
Clinically significant drug interactions frequently arise from specific, predictable pharmacokinetic mechanisms. Clarithromycin inhibits CYP3A4, preventing the metabolism of simvastatin and leading to toxic systemic levels. Hydrochlorothiazide induces mild volume depletion, prompting a compensatory increase in proximal tubular sodium reabsorption; lithium is reabsorbed alongside sodium, increasing the risk of toxicity. Omeprazole inhibits CYP2C19, the enzyme strictly required to convert clopidogrel from an inactive prodrug into its active form, leading to potential therapeutic failure (e.g., stent thrombosis). Verapamil inhibits P-glycoprotein, a vital efflux transporter for digoxin, thereby drastically decreasing digoxin's renal and biliary clearance and precipitating toxicity.

Step-by-Step Solution

1
Analyze the primary pharmacokinetic pathway for clearance or activation of the first drug in the pair.
Simvastatin relies on CYP3A4 for clearance; Clopidogrel requires CYP2C19 for activation; Digoxin relies on P-gp for excretion; Lithium relies on renal filtration and proximal tubular handling.
Understanding the baseline pharmacokinetics of the affected drug is necessary to identify how it can be disrupted.
2
Identify the pharmacological effect of the interacting drug on metabolic enzymes, transporters, or renal hemodynamics.
Clarithromycin inhibits CYP3A4; Omeprazole inhibits CYP2C19; Verapamil inhibits P-gp; Hydrochlorothiazide causes volume depletion, leading to compensatory proximal tubular reabsorption.
The interacting drug acts as the precipitant that alters the pharmacokinetics of the primary drug.
3
Pair the specific mechanism of the precipitant drug with the corresponding consequence on the affected drug.
The correct matches align the precise molecular or physiological interference with the resulting clinical vulnerability (e.g., toxicity vs. therapeutic failure).
Accurate pairing distinguishes between different types of pharmacokinetic disruptions (enzymatic, transporter-mediated, or renal).

Key Concept

Drug-drug interactions often manifest through specific pharmacokinetic alterations, primarily involving inhibition of cytochrome P450 enzymes (e.g., CYP3A4, CYP2C19), inhibition of efflux transporters (e.g., P-glycoprotein), or changes in renal tubular handling.
Question 174Question →

A 45-year-old man presents to the clinic complaining of a severe headache, tremors, and decreased urine output over the past two days. His medical history is significant for a deceased-donor renal transplant two years ago for IgA nephropathy. His daily medications include tacrolimus, mycophenolate mofetil, and prednisone. Eight days ago, he was evaluated at an urgent care center for a respiratory tract infection and was prescribed a 7-day course of clarithromycin. Today, his blood pressure is 165/95 mmHg, compared to 120/75 mmHg at his last visit. Laboratory studies show a serum creatinine of 2.2 mg/dL, elevated from his baseline of 1.1 mg/dL. Which of the following pharmacokinetic alterations regarding the patient's immunosuppressive regimen most likely occurred?

Show answer & explanation

Answer: Decreased systemic clearance resulting in a prolonged elimination half-life

Answer

Decreased systemic clearance resulting in a prolonged elimination half-life
Clarithromycin is a potent macrolide antibiotic that strongly inhibits the cytochrome P450 3A4 (CYP3A4) enzyme. Tacrolimus is a calcineurin inhibitor with a narrow therapeutic index that relies heavily on CYP3A4 for its hepatic metabolism. The addition of a strong CYP3A4 inhibitor significantly decreases the systemic clearance (ClCl) of tacrolimus. According to the foundational pharmacokinetic relationship t1/2=0.693×VdClt_{1/2} = \frac{0.693 \times Vd}{Cl}, a reduction in systemic clearance leads to a proportionally prolonged elimination half-life (t1/2t_{1/2}). This disruption results in elevated steady-state serum concentrations, manifesting clinically as calcineurin-inhibitor toxicity (e.g., acute kidney injury, new-onset or worsening hypertension, neurotoxicity such as tremors and headache).

Step-by-Step Solution

1
Identify the critical drug interaction in the vignette.
The patient is taking tacrolimus (a calcineurin inhibitor) and was recently prescribed clarithromycin (a macrolide antibiotic).
Recognizing interacting drug classes is the first step in diagnosing medication-induced adverse events.
2
Determine the pharmacokinetic mechanism of the interaction.
Clarithromycin is a strong inhibitor of the cytochrome P450 3A4 (CYP3A4) enzyme system. Tacrolimus is extensively metabolized by CYP3A4.
Understanding the metabolic pathways of narrow therapeutic index drugs is required to predict kinetic alterations.
3
Apply pharmacokinetic formulas to determine the clinical outcome.
Inhibiting CYP3A4 decreases the clearance (ClCl) of tacrolimus. Using the formula t1/2=0.693×VdClt_{1/2} = \frac{0.693 \times Vd}{Cl}, a decrease in clearance directly results in a prolonged half-life (t1/2t_{1/2}), leading to drug accumulation and nephrotoxicity (AKI, hypertension).
Linking enzymatic activity to standard kinetic variables confirms the exact physiological alteration.

Key Concept

Pharmacokinetic drug interactions via CYP3A4 inhibition
Question 175Question →

Match each clinical presentation with the corresponding underlying mechanism of cellular injury and tissue necrosis.

Click a left item, then click its matching right item

Items

A 68-year-old man with a history of atrial fibrillation undergoes emergency laparotomy for an infarcted small bowel segment.
A 72-year-old woman has follow-up brain imaging 8 months after a stroke, which reveals a fluid-filled cavity in the right cerebral hemisphere.
A 45-year-old man with night sweats and hemoptysis undergoes a lung biopsy showing a central region of friable, cheese-like material.
A 38-year-old woman with severe epigastric pain is diagnosed with acute pancreatitis, and imaging reveals chalky white peripancreatic deposits.

Matches

Show answer & explanation

Answer

The infarcted bowel matches with protein denaturation (coagulative necrosis); the remote brain infarct matches with lysosomal enzymatic dissolution (liquefactive necrosis); the cavitary lung lesion matches with macrophage-mediated amorphous debris (caseous necrosis); and acute pancreatitis matches with lipolysis and saponification (fat necrosis).
The question requires correlating clinical vignettes of tissue injury with specific pathophysiological mechanisms. Ischemia in the bowel causes coagulative necrosis via widespread denaturation of cellular proteins. In contrast, ischemia in the brain leads to liquefactive necrosis through rapid enzymatic digestion. Granulomatous infections like tuberculosis yield caseous necrosis, which appears as structureless debris. Lastly, the release of pancreatic enzymes triggers fat necrosis, leading to lipolysis and the formation of calcium soaps.

Step-by-Step Solution

1
Analyze each patient's clinical presentation to determine the affected organ and the primary pathological insult.
The cases describe small bowel ischemia, a remote ischemic stroke, a cavitary pulmonary infection (likely tuberculosis), and severe acute pancreatitis.
Identifying the specific organ system and insult is necessary to predict the resulting pattern of cell death.
2
Determine the specific type of necrosis associated with each clinical scenario.
Bowel ischemia causes coagulative necrosis; central nervous system ischemia causes liquefactive necrosis; mycobacterial infection causes caseous necrosis; and severe pancreatitis causes fat necrosis.
Different tissues exhibit distinct, predictable macroscopic and microscopic changes following irreversible cellular injury.
3
Match the identified type of necrosis to its defining molecular or cellular mechanism.
Coagulative matches protein denaturation; liquefactive matches enzymatic digestion; caseous matches structureless granulomatous debris; fat necrosis matches saponification.
This establishes the correlation between the macroscopic pathological findings and the foundational cellular mechanisms.

Key Concept

Mechanisms and histological patterns of tissue necrosis
Question 176Question →

A 59-year-old male is brought to the emergency department after a sudden syncopal episode at an airport following a 14-hour flight. Upon arrival, he is conscious but severely dyspneic. Vital signs include a blood pressure of 72/45 mmHg, heart rate of 138/min, respiratory rate of 32/min, and SpO2 of 81% on room air. Physical examination reveals prominent jugular venous distension, clear lungs to auscultation, and a right ventricular heave. An electrocardiogram shows sinus tachycardia and an S1Q3T3 pattern. The clinical picture is highly suggestive of a massive pulmonary embolism causing obstructive shock. Arrange the following management and diagnostic steps in the most appropriate sequential order for this patient.

Drag items to arrange them in the correct order

Show answer & explanation

Answer

The correct sequence prioritizes immediate stabilization, followed by empiric anticoagulation, bedside diagnostic confirmation, urgent reperfusion, and eventual long-term maintenance therapy.
The acute management of a massive pulmonary embolism (characterized by obstructive shock and right heart failure) follows a strict, life-saving sequence. First, immediate supportive care with oxygen and judicious intravenous fluids is required to treat hypoxia and optimize right ventricular preload. Second, because the clinical suspicion is exceptionally high, empiric anticoagulation is administered immediately to halt further clot propagation; this step must not be delayed for diagnostic testing. Third, a bedside transthoracic echocardiogram is performed. This patient is too hemodynamically unstable for a CT pulmonary angiogram, and a bedside echocardiogram rapidly identifies right ventricular strain to support the diagnosis safely. Fourth, upon confirming right heart failure, systemic thrombolytic therapy is administered to quickly reduce the clot burden and restore pulmonary perfusion. Finally, after the acute crisis has resolved and the patient is stabilized, parenteral anticoagulation is transitioned to a long-term oral anticoagulant for secondary prevention.

Step-by-Step Solution

1
Assess hemodynamic status and initiate supportive care.
The patient receives high-flow oxygen and intravenous fluids.
Securing airway, breathing, and circulation is the foundational first step in managing any critically ill patient in shock.
2
Initiate empiric systemic anticoagulation.
An unfractionated heparin drip is started immediately.
Clinical guidelines mandate immediate empiric anticoagulation for high-probability massive pulmonary embolism prior to imaging to prevent further catastrophic thrombus extension.
3
Perform bedside diagnostic testing.
A transthoracic echocardiogram confirms acute right ventricular overload and cor pulmonale.
The patient is too unstable for transport to the radiology suite for a CT pulmonary angiogram; bedside echocardiography safely provides actionable diagnostic evidence.
4
Administer definitive reperfusion therapy.
Systemic thrombolysis (alteplase) is delivered to actively dissolve the pulmonary thrombus.
Thrombolysis is the treatment of choice for a massive pulmonary embolism presenting with obstructive shock and confirmed right heart strain.
5
Transition to outpatient maintenance therapy.
The patient is eventually switched to a direct oral anticoagulant.
Once the acute hemodynamic crisis is resolved, long-term secondary prevention of venous thromboembolism is required.

Key Concept

The management of massive pulmonary embolism with hemodynamic instability requires immediate empiric anticoagulation and bedside echocardiography over transport-requiring imaging, followed by urgent thrombolytic reperfusion therapy.
Question 177Question →

A 54-year-old female presents to an outpatient nephrology clinic for rapid-onset swelling in her lower extremities and dark urine. She also reports progressive joint stiffness in her hands and knees over the past month, accompanied by a new, non-itchy rash on her shins. Her past medical history is significant for a brief period of intravenous drug use in her early twenties, but she has not sought medical care in over a decade. Her vital signs include a blood pressure of 152/94 mmHg. Physical examination demonstrates 2+ pitting edema to the knees and scattered, palpable purpuric lesions across both lower legs.

Laboratory testing reveals:
Serum creatinine: 1.9 mg/dL (Baseline unknown)
Urinalysis: 3+ protein, 20-30 red blood cells/hpf, dysmorphic red cells present
Rheumatoid factor: 420 IU/mL (Normal: < 15 IU/mL)
Complement C3: 92 mg/dL (Normal: 80-160 mg/dL)
Complement C4: 6 mg/dL (Normal: 15-45 mg/dL)
Hepatitis C virus RNA: 2.1 x 10^6 IU/mL

Which of the following best describes the fundamental immunopathologic mechanism driving this patient's current presentation?

Show answer & explanation

Answer: Formation of immune complexes by IgM autoantibodies binding to the Fc region of endogenous IgG

Answer

Formation of immune complexes by IgM autoantibodies binding to the Fc region of endogenous IgG
The correct answer accurately describes the underlying pathogenesis of mixed cryoglobulinemia. In mixed cryoglobulinemia (Types II and III), which is heavily associated with chronic Hepatitis C infection, the body produces IgM autoantibodies that specifically target the Fc region of endogenous IgG. These IgM antibodies are clinically measured as Rheumatoid Factor, which is highly elevated in this patient. When these IgM-IgG immune complexes form and deposit in small to medium-sized blood vessels, they strongly activate the classical complement pathway by binding C1q. This extensive classical pathway activation disproportionately consumes early complement components, leading to a characteristically profound decrease in serum C4 levels while C3 levels often remain normal or only mildly depressed.

Step-by-Step Solution

1
Analyze the clinical syndrome presented in the vignette.
The patient exhibits the classic triad of palpable purpura, arthralgias, and weakness/fatigue, accompanied by new-onset glomerulonephritis (edema, hypertension, hematuria with dysmorphic RBCs). The history of intravenous drug use provides a strong risk factor for chronic viral hepatitis.
Identifying the overarching clinical syndrome narrows the differential diagnosis of systemic vasculitis with renal involvement.
2
Interpret the specific laboratory findings to identify the underlying immunopathologic mechanism.
The presence of Hepatitis C virus, highly elevated rheumatoid factor, and a profoundly depressed C4 level with a normal C3 level point directly to mixed cryoglobulinemia.
Rheumatoid factor is an IgM autoantibody against IgG. Hepatitis C is the most common trigger for mixed cryoglobulinemia (Type II or III). The isolated, severe C4 consumption confirms massive classical complement pathway activation by these specific immune complexes.

Key Concept

Mixed cryoglobulinemia (Type II and III) is strongly associated with chronic Hepatitis C infection and is driven by IgM autoantibodies (rheumatoid factor) forming immune complexes with endogenous IgG, leading to classical complement pathway activation and profound C4 consumption.
Question 178Question →

A 29-year-old nulliparous woman is evaluated in the outpatient clinic for preconception counseling. Her medical history is significant for an unprovoked deep venous thrombosis in her right lower extremity three years ago, which was treated with a 6-month course of oral anticoagulation. She has no history of spontaneous bruising, epistaxis, or prolonged bleeding following minor injuries or dental procedures. Her physical examination is unremarkable. Laboratory studies obtained as part of her preconception workup reveal a normal prothrombin time (PT) and a platelet count of 210,000/mm³. However, her activated partial thromboplastin time (aPTT) is 58 seconds (normal: 25-40 seconds). An immediate 1:1 mixing study with normal pooled plasma fails to correct the aPTT into the normal reference range. Which of the following best describes the pathophysiologic mechanism responsible for this patient's abnormal coagulation assay?

Show answer & explanation

Answer: In vitro binding of immunoglobulins to phospholipid-protein complexes

Answer

The mechanism is the in vitro binding of immunoglobulins to phospholipid-protein complexes.
The correct answer accurately describes the mechanism of a lupus anticoagulant (LA) in antiphospholipid syndrome (APS). LAs are autoantibodies directed against phospholipid-binding proteins. In vitro, they bind to the phospholipids used in the aPTT assay, disrupting the assembly of the prothrombinase complex and thereby prolonging the clotting time. Because the etiology is a circulating antibody, adding normal plasma (mixing study) does not overcome the inhibition, and the aPTT remains prolonged. Paradoxically, in vivo, these antibodies activate endothelial cells, monocytes, and platelets, driving a hypercoagulable state characterized by recurrent venous or arterial thromboses (such as this patient's prior DVT) or adverse pregnancy outcomes.

Step-by-Step Solution

1
Analyze the patient's clinical history.
The patient has a history of an unprovoked deep venous thrombosis (prothrombotic state) with no history of bleeding diathesis.
Establishing the clinical phenotype helps rule out bleeding disorders and points toward hypercoagulable states.
2
Interpret the laboratory findings and the mixing study.
The patient has an isolated prolonged aPTT with a normal PT and normal platelets. The aPTT fails to correct on a 1:1 mixing study.
A failure to correct upon mixing with normal plasma indicates the presence of an inhibitor (such as an antibody) rather than a coagulation factor deficiency.
3
Correlate the clinical phenotype with the laboratory inhibitor profile.
The combination of an inhibitor (non-correcting aPTT) and a clinical history of thrombosis is highly specific for the presence of a lupus anticoagulant (antiphospholipid syndrome).
Factor inhibitors (like factor VIII antibodies) cause severe bleeding. Lupus anticoagulants cause an in vitro artifact (prolonged aPTT) but an in vivo prothrombotic tendency.

Key Concept

Patients with a lupus anticoagulant exhibit a paradoxical prolongation of the aPTT that fails to correct on a mixing study, despite having an in vivo hypercoagulable state that predisposes them to venous or arterial thrombosis.
Question 179Question →

A 4-year-old boy is brought to the emergency department with a 3-day history of severe, crampy abdominal pain and grossly bloody diarrhea. His parents report that he attended a neighborhood cookout one week ago where he consumed a hamburger. Initial laboratory studies reveal severe thrombocytopenia, microangiopathic hemolytic anemia with schistocytes on peripheral smear, and an elevated serum creatinine level. The child's condition is caused by a bacterial exotoxin. Arrange the following steps in the precise molecular pathogenesis of this toxin in sequential chronological order, from initial host cell interaction to final cellular consequence.

Drag items to arrange them in the correct order

Show answer & explanation

Answer

The correct sequence of Shiga-like toxin pathogenesis begins with extracellular binding to Gb3 receptors, followed by endocytosis and retrograde transport, translocation of the active A-subunit into the cytoplasm, depurination of the 28S rRNA, and finally, the cessation of protein synthesis leading to cell death.
The correct sequence describes the established pathophysiological cascade of Shiga-like toxin (produced by Enterohemorrhagic Escherichia coli). The toxin is an AB5 multimeric exotoxin. First, the five B-subunits bind to globotriaosylceramide (Gb3) receptors, which are highly expressed on the surface of intestinal mucosa and renal glomerular endothelial cells. Following binding, the entire toxin complex is internalized via receptor-mediated endocytosis and undergoes retrograde transport through the Golgi network to the endoplasmic reticulum. Within the endoplasmic reticulum, the catalytically active A-subunit is cleaved and translocated into the host cell cytoplasm. The A-subunit then acts as an N-glycosidase, specifically removing an adenine nucleobase from the 28S ribosomal RNA of the 60S ribosomal subunit. This depurination prevents the binding of elongation factor-1 (EF-1), thereby completely halting host cell protein synthesis. The sudden arrest in translation leads to endothelial cell apoptosis, exposing subendothelial collagen and prompting the widespread formation of platelet-rich microthrombi characteristic of Hemolytic Uremic Syndrome.

Step-by-Step Solution

1
Identify the clinical syndrome and the causative pathogen's primary virulence factor.
The patient has Hemolytic Uremic Syndrome (HUS) secondary to an infection with Enterohemorrhagic Escherichia coli (EHEC), which produces Shiga-like toxin.
A presentation of bloody diarrhea following undercooked beef consumption, progressing to the triad of microangiopathic hemolytic anemia, thrombocytopenia, and acute kidney injury is classic for EHEC.
2
Sequence the extracellular and intracellular transport phases of the toxin.
The B-subunit first binds to Gb3 receptors, leading to endocytosis and retrograde transport to the endoplasmic reticulum.
AB5 toxins must first dock to specific host cell receptors (Gb3 for Shiga toxin) on the membrane surface to trigger internalization.
3
Sequence the intracellular enzymatic phase.
The A-subunit is translocated into the cytoplasm, where it cleaves an adenine from the 28S rRNA.
Once in the cytoplasm, the active subunit targets the 60S ribosome to disrupt its normal enzymatic function.
4
Determine the terminal cellular outcome.
Host cell protein synthesis halts, causing endothelial cell apoptosis and subsequent microthrombi formation.
Inactivation of the ribosome inherently stops translation, causing the widespread endothelial damage that triggers the coagulation cascade seen in HUS.

Key Concept

Pathogenesis of Shiga and Shiga-like toxins via Gb3 receptor binding and 60S ribosomal subunit inactivation.
Question 180Question →

A 39-year-old construction worker, maintained on chronic high-dose oral morphine therapy for severe lumbar radiculopathy, presents to the emergency department after sustaining a traumatic anterior shoulder dislocation. For pre-procedural analgesia prior to joint reduction, the attending physician administers a standard intravenous dose of buprenorphine. Within fifteen minutes, the patient begins exhibiting profound diaphoresis, mydriasis, piloerection, and intense psychomotor agitation. Vital signs reveal a heart rate of 128/min and blood pressure of 168/98 mmHg. Which of the following pharmacologic principles best explains the mechanism underlying this patient's acute clinical deterioration?

Show answer & explanation

Answer: The administered agent has a lower dissociation constant (KdK_d) and a lower maximal efficacy (EmaxE_{max}) than the maintenance medication.

Answer

The administered analgesic displaces the home medication because it has a higher receptor affinity (a lower dissociation constant, KdK_d) but precipitates withdrawal because it produces a weaker biological response (a lower maximal efficacy, EmaxE_{max}).
The correct answer identifies that the administered drug (buprenorphine) displaces the maintenance drug (morphine) because it binds more tightly to the receptor, reflected by a lower dissociation constant (KdK_d). However, because it is only a partial agonist, it cannot fully activate the receptor, meaning it has a lower maximal efficacy (EmaxE_{max}). In an opioid-dependent patient, this sudden replacement of a high-efficacy drug with a low-efficacy drug causes a massive net drop in mu-opioid receptor signaling, instantly precipitating withdrawal.

Step-by-Step Solution

1
Analyze the patient's clinical presentation.
The sudden onset of diaphoresis, mydriasis, piloerection, tachycardia, and agitation in a patient dependent on high-dose morphine represents acute opioid withdrawal.
Recognizing the syndrome is required to determine the mechanism of the adverse drug event.
2
Identify the pharmacological properties of the administered drug.
Buprenorphine was administered. Buprenorphine is a partial mu-opioid agonist, meaning it binds strongly to the receptor but activates it only partially.
Understanding the drug class allows translation into specific pharmacokinetic and pharmacodynamic parameters.
3
Translate the drug properties into pharmacodynamic variables.
High binding affinity correlates with a low dissociation constant (KdK_d). Partial activation correlates with a low maximal efficacy (EmaxE_{max}) compared to a full agonist like morphine.
The correct answer must describe how buprenorphine displaces morphine (low KdK_d) while providing inadequate opioid stimulation to prevent withdrawal (low EmaxE_{max}).

Key Concept

Buprenorphine is a partial mu-opioid agonist with a lower dissociation constant (KdK_d, indicating higher affinity) and a lower maximum efficacy (EmaxE_{max}) than full agonists like morphine, allowing it to precipitate withdrawal in opioid-dependent patients.
PreviousPage 9 / 22Next
Foundational Science and Mechanisms of Disease Practice Questions — USMLE Step 3 — Page 9 | Examkin